Interpretation of creatine kinase and aldolase for statin-induced myopathy: Reliance on serial testing based on biological variation

Clinica Chimica Acta

Volumn 399, Issue 1-2, 2009, Pages 109-111

  Wu, Alan H B ^a   Smith, Andrew ^a   Wians, Frank ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aldolase; Biological variation; Creatine kinase; Myopathy; Statins

Indexed keywords

CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BLOOD SAMPLING; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MYOPATHY; MYOSITIS; NORMAL HUMAN; PRIORITY JOURNAL; REFERENCE VALUE;

ADULT; ALGORITHMS; ANTICHOLESTEREMIC AGENTS; CLINICAL ENZYME TESTS; CREATINE KINASE; CREATININE; FEMALE; FRUCTOSE-BISPHOSPHATE ALDOLASE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MUSCULAR DISEASES; NATRIURETIC PEPTIDE, BRAIN; REFERENCE VALUES; SIMVASTATIN; TIME FACTORS;

EID: 57049124829     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.09.023     Document Type: Article

References (24)

1. Chan J., Hui R.L., and Levin E. Differential association between statin exposure and elevated levels of creatine kinase. Ann Pharmacogher 39 (2005) 1611-1616
2. Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol 97 [suppl] (2006) 6C-26C
3. Nichols G.A., and Koro C.E. Does statin therapy initiation increase the risk for myopathy? An observation study of 32,225 diabetics and nondiabetic patients. Clin Ther 29 (2007) 1761-1770
4. McKenney J.M., Davidson M.H., Jacobson T.A., and Guyton J.R. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97[suppl] (2006) S89-S94
5. Kashani A., Phillips C.O., Foody J.M., Wang Y., Mangalmurti S., Ko D.T., et al. Risk associated with statin therapy. A systematic overview of randomized clinical trials. Circulation 114 (2006) 2788-2797
6. Rosalki S.B. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med 69 (1967) 696-705
7. Brewster L.M., Mairuhu G., Sturk A., and van Montfrans G.A. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J 154 (2007) 655-661
8. Dobkins B.H. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil Neural Repair 19 (2005) 259-263
9. Troseid M., Henriksen O.A., and Lindal S. Statin-associated myopathy with normal creatine kinase levels. Case report from a Norwegian family. APMIS 113 (2005) 635-637
10. Fraser C.G., and Harris E.K. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 27 (1989) 409-437
11. Gunst J.J., Langois M.R., Delanghe J.R., De Buyzere M.L., and Leroux-Roels G.G. Serum creatine kinase activity is not a reliable marker for muscle damage in conditions associated with low extracellular glutathione concentration. Clin Chem 44 (1998) 939-943
12. Gutenbrunner C. Circadian variation of the serum creatine kinase level. A masking effect?. Chronbiol Int 17 (2000) 583-590
13. Fokkema M.R., Herrmann Z., Muskiet F.A.J., and Moecks J. Reference change values for brain natriuretic peptides revisited. Clin Chem 52 (2006) 1602-1603
14. Wu A.H.B., Smith A.C., Mather J.F., Duncan B., White C.M., Ahlberg A., et al. Biological variation for NT-pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92 (2003) 628-631
15. Macey E.M., Hayes T.E., and Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43 (1997) 52-58
16. Wu AHB, Lu A, Todd J, Moecks J, Wians F. Short- and long-term biological variation for cardiac troponin I using a high sensitivity assay: implications for clinical practice. Clin Chem in press.
17. Ross S.M., and Fraser C.G. Biological variation of cardiac markers: analytical and clinical considerations. Ann Clin Biochem 35 (1998) 80-84
18. Baker S.K., and Samjoo I.A. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci 35 (2008) 8-21
19. Jacobson T.A. Towards "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 83 (2008) 687-700
20. Pasternak R.C., Smith S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., and Lenfant C. ACC/AHA /NHLBI clinical advisory on the use and safety of statins. Circulation 106 (2002) 1024-1028
21. Expert Panel on Detection, and Treatment of High Blood Cholesterol in Adults. Final report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002), National Heart Blood and Lung Institute 171. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf
22. Hilton-Jones D. Myopathy associated with statin therapy. Neuromuscul Dis 18 (2008) 97-98
23. Tragni E., Filippi A., Mazzaglia G., Sessa E., Cricelli C., and Catapano Professor A.L. Monitoring statin safety in primary care. Pharmacoepidemiol Drug Safety 16 (2007) 652-657
24. Sniderman A.D. Is there value in liver function test and creatine phosphokinase monitoring with statin use. Am J Cardiol 94[suppl] (2004) 30F-34F